Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease : The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology..
INTRODUCTION: Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors of EIMs. The aim of this study was to prospectively investigate the epidemiology, risk factors of EIM occurrence, and EIM remission in a large IBD cohort.
METHODS: We conducted a cross-sectional study in 30 French referral centers. Between May 2021 and June 2021, all consecutive patients attending to hospital appointment were systematically invited to fill out a questionnaire.
RESULTS: A total of 1,971 consecutive patients with IBD were analyzed. There were 1,056 women (53.8%), and the median age of patients was 41 years (31-54). The median disease duration was 11 years (1-18). Overall, 544 (27.6%) had at least 1 EIM. In 20.2% of cases, patients had multiple EIMs. The most frequent EIMs were rheumatological (19%) and dermatological (10%) manifestations. Immunosuppressant treatment (odds ratio [OR] = 2.56; P < 0.001) was a risk factor of EIM, while the Montreal A3 classification (OR = 0.61, P = 0.023) and male gender (OR = 0.61, P < 0.001) were associated with a lower risk of EIM occurrence. IBD current clinical remission (OR = 2.42; P < 0.001) and smoking cessation (OR = 2.98; P < 0.001) were associated factors of EIM remission. Conversely, age at IBD diagnosis (OR = 0.98; P < 0.018) was associated with a lower risk of EIM remission.
DISCUSSION: One quarter of patients had at least 1 EIM. Beyond factors associated with the presence of EIMs, patients with IBD current clinical remission and smoking cessation are more likely to achieve EIM remission, while increasing age at IBD diagnosis is associated with decreased chance of remission.
| Errataetall: |
CommentIn: Clin Transl Gastroenterol. 2023 Dec 01;14(12):e00618. - PMID 38156785 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Clinical and translational gastroenterology - 14(2023), 12 vom: 01. Dez., Seite e00607 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guillo, Lucas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.01.2024 Date Revised 17.04.2024 published: Electronic CommentIn: Clin Transl Gastroenterol. 2023 Dec 01;14(12):e00618. - PMID 38156785 Citation Status MEDLINE |
|---|
| doi: |
10.14309/ctg.0000000000000607 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360232531 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360232531 | ||
| 003 | DE-627 | ||
| 005 | 20240417232155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14309/ctg.0000000000000607 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM360232531 | ||
| 035 | |a (NLM)37523417 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guillo, Lucas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease |b The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.01.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentIn: Clin Transl Gastroenterol. 2023 Dec 01;14(12):e00618. - PMID 38156785 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. | ||
| 520 | |a INTRODUCTION: Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors of EIMs. The aim of this study was to prospectively investigate the epidemiology, risk factors of EIM occurrence, and EIM remission in a large IBD cohort | ||
| 520 | |a METHODS: We conducted a cross-sectional study in 30 French referral centers. Between May 2021 and June 2021, all consecutive patients attending to hospital appointment were systematically invited to fill out a questionnaire | ||
| 520 | |a RESULTS: A total of 1,971 consecutive patients with IBD were analyzed. There were 1,056 women (53.8%), and the median age of patients was 41 years (31-54). The median disease duration was 11 years (1-18). Overall, 544 (27.6%) had at least 1 EIM. In 20.2% of cases, patients had multiple EIMs. The most frequent EIMs were rheumatological (19%) and dermatological (10%) manifestations. Immunosuppressant treatment (odds ratio [OR] = 2.56; P < 0.001) was a risk factor of EIM, while the Montreal A3 classification (OR = 0.61, P = 0.023) and male gender (OR = 0.61, P < 0.001) were associated with a lower risk of EIM occurrence. IBD current clinical remission (OR = 2.42; P < 0.001) and smoking cessation (OR = 2.98; P < 0.001) were associated factors of EIM remission. Conversely, age at IBD diagnosis (OR = 0.98; P < 0.018) was associated with a lower risk of EIM remission | ||
| 520 | |a DISCUSSION: One quarter of patients had at least 1 EIM. Beyond factors associated with the presence of EIMs, patients with IBD current clinical remission and smoking cessation are more likely to achieve EIM remission, while increasing age at IBD diagnosis is associated with decreased chance of remission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Savoye, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Amiot, Aurélien |e verfasserin |4 aut | |
| 700 | 1 | |a Gilletta, Cyrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Nachury, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Dib, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Bourreille, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Roblin, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Caillo, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Allez, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Picon, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Hébuterne, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Seksik, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Chupin, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Buisson, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Brixi, Hédia |e verfasserin |4 aut | |
| 700 | 1 | |a Altwegg, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Amil, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Laharie, David |e verfasserin |4 aut | |
| 700 | 1 | |a Bouguen, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Serrero, Mélanie |e verfasserin |4 aut | |
| 700 | 1 | |a Elgharabawy, Yasmine |e verfasserin |4 aut | |
| 700 | 1 | |a Peyrin-Biroulet, Laurent |e verfasserin |4 aut | |
| 700 | 0 | |a EXTRA Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational gastroenterology |d 2010 |g 14(2023), 12 vom: 01. Dez., Seite e00607 |w (DE-627)NLM223422886 |x 2155-384X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:e00607 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14309/ctg.0000000000000607 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 12 |b 01 |c 12 |h e00607 | ||